Literature DB >> 23902128

Alexithymia in patients with conversion disorder.

Demet Gulpek1, Figen Kelemence Kaplan, Sermin Kesebir, Ozlem Bora.   

Abstract

BACKGROUND AND AIMS: In the recent years, it has been observed that alexithymia is not specified for the psychosomatic disorders. It is known that alexithymia is observed frequently in various psychiatric disorders especially in the somatoform disorders. The aim of this study is to evaluate alexithymia in the patients with the conversion disorder.
METHODS: The study was performed in the Psychiatry Outpatients Clinics of the Izmir Atatürk Training and Research Hospital and Erenköy Psychiatry Education and Research Hospital. A total of 93 cases-47 outpatients who were diagnosed with conversion disorder according to the DSM-IV criteria and 46 age, gender and educational level matched healthy controls-were included in the study. All the cases were assessed by a Structured Clinical Interview for DSM-IV and were evaluated with a questionnaire (which included demographics and clinical data), the Toronto Alexithymia Scale and the Somatosensory Amplification Scale.
RESULTS: When the two groups were compared, the Toronto Alexithymia Scale scores (except "externally oriented thinking" subscale) and the Somatosensory Amplification Scale score of the conversion disorder group were statistically significantly higher than the control group. The number of the alexithymic cases of the patient group was significantly higher than the control group's.
CONCLUSIONS: The level of alexithymia in conversion disorder patients, without any other psychiatric disorder, is higher than that of the healthy controls. During the evaluation of the psychological state of patients with conversion disorder, it could be useful to keep in mind the probability of them having alexithymia to determine the type of suitable therapy.

Entities:  

Keywords:  Alexithymia; Conversion disorder; Somatisation; Somatosensory amplification

Mesh:

Year:  2013        PMID: 23902128     DOI: 10.3109/08039488.2013.814711

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  6 in total

1.  Resilience linked to personality dimensions, alexithymia and affective symptoms in motor functional neurological disorders.

Authors:  Rozita Jalilianhasanpour; Benjamin Williams; Isabelle Gilman; Matthew J Burke; Sean Glass; Gregory L Fricchione; Matcheri S Keshavan; W Curt LaFrance; David L Perez
Journal:  J Psychosom Res       Date:  2018-02-13       Impact factor: 3.006

2.  The role of language in emotion: predictions from psychological constructionism.

Authors:  Kristen A Lindquist; Jennifer K MacCormack; Holly Shablack
Journal:  Front Psychol       Date:  2015-04-14

3.  Somatoform dissociation and posttraumatic stress syndrome - two sides of the same medal? A comparison of symptom profiles, trauma history and altered affect regulation between patients with functional neurological symptoms and patients with PTSD.

Authors:  Johanna Kienle; Brigitte Rockstroh; Martin Bohus; Johanna Fiess; Silke Huffziger; Astrid Steffen-Klatt
Journal:  BMC Psychiatry       Date:  2017-07-11       Impact factor: 3.630

4.  Prevalence and correlates of alexithymia in older persons with medically (un)explained physical symptoms.

Authors:  Pauline Bos; Richard C Oude Voshaar; Denise J C Hanssen
Journal:  Int J Geriatr Psychiatry       Date:  2022-05-09       Impact factor: 3.850

5.  Variation of Functional Neurological Symptoms and Emotion Regulation with Time.

Authors:  Johanna Kienle; Brigitte Rockstroh; Johanna Fiess; Roger Schmidt; Tzvetan Popov; Astrid Steffen-Klatt
Journal:  Front Psychiatry       Date:  2018-02-13       Impact factor: 4.157

6.  Explicit and Implicit Components of the Emotional Processing in Non-organic Vision Loss: Behavioral Evidence About the Role of Fear in Functional Blindness.

Authors:  Federica Scarpina; Lisa Melzi; Gianluca Castelnuovo; Alessandro Mauro; Stefania B Marzoli; Enrico Molinari
Journal:  Front Psychol       Date:  2018-04-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.